Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Chronic-Obstructive-Pulmonary-Disease"

67 News Found

Lupin and Sino Universal Pharmaceuticals sign license and supply agreement for tiotropium DPI in China
News | June 17, 2025

Lupin and Sino Universal Pharmaceuticals sign license and supply agreement for tiotropium DPI in China

SUP will obtain regulatory approvals for selling Tiotropium DPI in China


Lupin to use Honeywell’s HFO technology in inhalers
News | May 21, 2025

Lupin to use Honeywell’s HFO technology in inhalers

Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants


AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
Clinical Trials | May 03, 2025

AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease


Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD
News | March 29, 2025

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD

Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)


Aerogen opens India HQ in New Delhi
News | March 20, 2025

Aerogen opens India HQ in New Delhi

The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India


GSK's Nucala application for COPD accepted for review in China
Drug Approval | February 21, 2025

GSK's Nucala application for COPD accepted for review in China

Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally


Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Drug Approval | September 27, 2024

Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype


Strides receive USFDA approval for Theophylline ER tablets, 300 mg and 450 mg
Drug Approval | September 06, 2024

Strides receive USFDA approval for Theophylline ER tablets, 300 mg and 450 mg

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug